Past a turning point, Finch scores $90M to complete the final stretch for oral microbiome therapy
Back in 2017, Finch Therapeutics was born, shrouded in the ashes of an implosion at Seres Therapeutics that clouded the whole microbiome field. But co-founder Mark Smith managed to pool together some angel money and a $5.5 million Series A before landing $10 million upfront from a pact with Takeda.
Smith slowly attracted more believers — racking up a breakthrough therapy designation, grabbing a new lead program through a merger with Crestovo, expanding the Takeda partnership — and brought in $53 million in Series B cash to fund a crucial Phase II study.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
